The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Unintended Consequences of Caps on Medicare Drug Benefits
Abstract
BACKGROUND: Little information exists about the consequences of limits on prescription-drug benefits for Medicare beneficiaries. METHODS: We compared the clinical and economic outcomes in 2003 among 157,275 Medicare+Choice beneficiaries whose annual drug benefits were capped at 1,000 dollars and 41,904 beneficiaries whose drug benefits were unlimited because of employer supplements. RESULTS: After adjusting for individual characteristics, we found that subjects whose benefits were capped had pharmacy costs for drugs applicable to the cap that were lower by 31 percent than subjects whose benefits were not capped (95 percent confidence interval, 29 to 33 percent) but had total medical costs that were only 1 percent lower (95 percent confidence interval, -4 to 6 percent). Subjects whose benefits were capped had higher relative rates of visits to the emergency department (relative rate, 1.09 [95 percent confidence interval, 1.04 to 1.14]), nonelective hospitalizations (relative rate, 1.13 [1.05 to 1.21]), and death (relative rate, 1.22 [1.07 to 1.38]; difference, 0.68 per 100 person-years [0.30 to 1.07]). Among subjects who used drugs for hypertension, hyperlipidemia, or diabetes in 2002, those whose benefits were capped were more likely to be nonadherent to long-term drug therapy in 2003; the respective odds ratios were 1.30 (95 percent confidence interval, 1.23 to 1.38), 1.27 (1.19 to 1.34), and 1.33 (1.18 to 1.48) for subjects using drugs for hypertension, hyperlipidemia, and diabetes. In each subgroup, the physiological outcomes were worse for subjects whose drug benefits were capped than for those whose benefits were not capped; the odds ratios were 1.05 (95 percent confidence interval, 1.00 to 1.09), 1.13 (1.03 to 1.25), and 1.23 (1.03 to 1.46), respectively, for subjects with a systolic blood pressure of 140 mm Hg or more, a serum low-density-lipoprotein cholesterol level of 130 mg per deciliter or more, and a glycated hemoglobin level of 8 percent or more. CONCLUSIONS: A cap on drug benefits was associated with lower drug consumption and unfavorable clinical outcomes. In patients with chronic disease, the cap was associated with poorer adherence to drug therapy and poorer control of blood pressure, lipid levels, and glucose levels. The savings in drug costs from the cap were offset by increases in the costs of hospitalization and emergency department care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Oehlert, G. W. (1992) · The American Statistician · doi:10.1080/00031305.1992.10475842 · Cited by 1,379
Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons
Tamblyn, R. (2001) · JAMA · doi:10.1001/jama.285.4.421 · Cited by 873
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes
Soumerai, S. B., Ross-Degnan, D., Avorn, J., McLaughlin, T. J., & Choodnovskiy, I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110103251505 · Cited by 505
Steiner, J. F., Koepsell, T. D., Fihn, S. D., & Inui, T. S. (1988) · Medical Care · doi:10.1097/00005650-198808000-00007 · Cited by 458
Payment Restrictions for Prescription Drugs under Medicaid
Soumerai, S. B., Avorn, J., Ross-Degnan, D., & Gortmaker, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170906 · Cited by 409
Chapter 8 Moral hazard and consumer incentives in health care
Zweifel, P., & Manning, W. G. (2000) · Handbook of Health Economics · doi:10.1016/s1574-0064(00)80167-5 · Cited by 389
Piette, J. D., Heisler, M., & Wagner, T. H. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.10.1782 · Cited by 349
Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission
Valenstein, M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2002) · Medical Care · doi:10.1097/00005650-200208000-00002 · Cited by 338
Medication Costs, Adherence, And Health Outcomes Among Medicare Beneficiaries
Mojtabai, R., & Olfson, M. (2003) · Health Affairs · doi:10.1377/hlthaff.22.4.220 · Cited by 321
Termination from Medi-Cal — Does It Affect Health?
Lurie, N., Ward, N. B., Shapiro, M. F., & Brook, R. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408163110735 · Cited by 302
Lack of Health Insurance and Decline in Overall Health in Late Middle Age
Baker, D. W., Sudano, J. J., Albert, J. M., Borawski, E. A., & Dor, A. (2001) · New England Journal of Medicine · doi:10.1056/nejmsa002887 · Cited by 270
Steinman, M. A., Sands, L. P., & Covinsky, K. E. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.10412.x · Cited by 246
Employer Drug Benefit Plans and Spending on Prescription Drugs
Joyce, G. F. (2002) · JAMA · doi:10.1001/jama.288.14.1733 · Cited by 228
Federman, A. D. (2001) · JAMA · doi:10.1001/jama.286.14.1732 · Cited by 169
Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action
Soumerai, S. B., & Ross-Degnan, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400909 · Cited by 168
Tseng, C. (2004) · JAMA · doi:10.1001/jama.292.8.952 · Cited by 140
Freemantle, N., & Bloor, K. E. (1996) · BMJ · doi:10.1136/bmj.312.7044.1469 · Cited by 126
Measuring population health risks using inpatient diagnoses and outpatient pharmacy data.
Zhao, Y., Ellis, R. P., Ash, A. S., Calabrese, D., Ayanian, J. Z., Slaughter, J., Weyuker, L., & Bowen, B. (2001) · Europe PMC (PubMed Central) · Cited by 82
Medicare Beneficiaries??? Management of Capped Prescription Benefits
Cox, E. R., Jernigan, C., Coons, S. J., et al. (2001) · Medical Care · doi:10.1097/00005650-200103000-00009 · Cited by 75
Do Drug Benefits Help Medicare Beneficiaries Afford Prescribed Drugs?
Rector, T. S., & Venus, P. J. (2004) · Health Affairs · doi:10.1377/hlthaff.23.4.213 · Cited by 56
Assessing The Impact Of Coverage Gaps In The Medicare Part D Drug Benefit
Stuart, B., Simoni, J. M., & Chauncey, D. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.167 · Cited by 56
Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients
Tseng, C. (2003) · JAMA · doi:10.1001/jama.290.2.222 · Cited by 49
Krieger, N., & Gordon, D. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010095 · Cited by 46
Cited by
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488
Best care at lower cost: the path to continuously learning health care in America
(2014) · Choice Reviews Online · doi:10.5860/choice.51-3277 · Cited by 1,363
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Technology Growth and Expenditure Growth in Health Care
Chandra, A., & Skinner, J. (2012) · Journal of Economic Literature · doi:10.1257/jel.50.3.645 · Cited by 412
Metadata
- Authors
- Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., Fireman, B., Newhouse, J. P., & Selby, J. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-06
- Volume
- 354
- Issue
- 22
- Pages
- 2349-2359
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2039998796
- Cited by
- 371
- References
- 26
- FWCI
- 109.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.